A prospective, double-blinded, randomized, placebo-controlled phase 1/2a study to assess safety, tolerability, systemic exposure, and preliminary efficacy of single intraarticular injections of 3 dose levels of SYN321 and placebo in patients with symptomatic knee osteoarthritis. - Trial 2022-003633-19
Access comprehensive clinical trial information for 2022-003633-19 through Pure Global AI's free database. This phase not specified trial is sponsored by Synartro AB and is currently Ongoing. The study focuses on Knee osteoarthritis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Synartro AB
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results or the patient’s ability to participate in the study.
ICD-10 Classifications
Data Source
EU Clinical Trials Register
2022-003633-19
Non-Device Trial